Citable filing context

LLY filing events and research context

Server-rendered

LLY's research view summarizes recent SEC filing context, starting with earnings from Apr 30, 2026.

LLY filing events and research context
FiledItemContext
Apr 30, 2026earningsEli Lilly and Company reported its financial results.
Feb 4, 2026earningsEli Lilly & Co. reported its results of operations and financial condition.
Nov 21, 2025management_changeReports changes in directors, officers, and compensatory arrangements.
Apr 30, 2026Guidance: non_gaap_eps35.50 to 37.00
Apr 30, 2026Guidance: performance_margin47.00 to 48.50
Apr 30, 2026Guidance: revenue82.00 to 85.00
Apr 30, 2026mda_quarterlyDuring the three months ended March 31, 2026, Eli Lilly and Company executed significant share repurchases, buying back 2.376 million shares of its equity securities. The average price paid per share was $987.15, amounting to a total expenditure of $2.3 billion. This activity is part of a larger $15.0 billion share repurchase program authorized by the board in December 2024, with approximately $8.573 billion remaining available for future repurchases as of the end of March 2026. Separately, several key executives established Rule 10b5-1 sales plans in February 2026. Anat Hakim, Executive Vice President, General Counsel and Secretary, adopted a plan to sell up to 10,000 shares between August 7, 2026, and November 30, 2026. Ilya Yuffa, Executive Vice President and President Lilly USA and Global Customer Capabilities,
Feb 12, 2026businessEli Lilly and Company is a global pharmaceutical firm focused on discovering, developing, manufacturing, and marketing human pharmaceutical products. Its portfolio spans several key therapeutic areas. In Cardiometabolic Health, major products include Mounjaro and Zepbound for diabetes and obesity, Jardiance and Trulicity for diabetes, often in collaboration with Boehringer Ingelheim. The Oncology segment features Verzenio for breast cancer, Jaypirca for hematologic malignancies, and Retevmo for NSCLC and thyroid cancers. Immunology products include Olumiant for rheumatoid arthritis and atopic dermatitis, and Taltz for psoriasis. Neuroscience is represented by Emgality for migraine and Kisunla for early Alzheimer's disease. Lilly operates globally, selling products in approximately 90 countries with manufacturing in the U.S., Europe, and Asia. U.S. distribution relies heavily on three major wholesalers—McKesson, Cencora, and Cardinal Health—each contributing significantly to consolidated revenue. The company is also expanding its direct-to-patient digital healthcare platform, LillyDirect, for select medicines, which represents a growing portion of its business.

Source: SEC EDGAR filing text and events; period Apr 30, 2026; filed Apr 30, 2026.

Continue research

Keep researching LLY

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →
AMGN
AMGEN INC
$186.59B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →